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Abstract 
Purpose: To investigate whether myricetin ameliorates lipopolysaccharide (LPS)-induced acute lung 
inflammation (ALI) in a rat model, and to elucidate the probable molecular mechanism of action 
involved.  
Methods: Myricetin (10, 20 and 40 mg/kg) was administered to rats 30 min after intratracheally 
administering LPS (5 mg/kg). BALF protein concentration, lung wet-to-dry weight ratio, myeloperoxidase 
(MPO) activity, cytokine production and migration of inflammatory cells were evaluated.  
Results: Myricetin significantly (p ≤ 0.05) attenuated lung inflammation as evident from the decreased 
wet-to-dry weight ratio of lungs, concentration of protein in the BALF, activity of MPO, cytokine 
production, and inflammatory cell migration. A decrease was also seen in TLR4, MyD88 and NF-κB 
expression. Additionally, an elevated antioxidant enzyme activity of superoxide dismutase (SOD), 
glutathione peroxidase (GPx) and catalase (CAT) was observed in all the treatment groups.  
Conclusion: Myricetin provides protection against LPS-induced ALI. The underlying mechanisms of its 
anti-inflammatory action may include inhibition of NF-κB-mediated inflammatory responses. 
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Acute lung injury (ALI) causes extensive 
disruption of blood-air barrier, leading to the 
development of acute respiratory failure and 
capillary edema, and hence making it a life-
threatening clinical disorder. Together, these 
effects result in high mortality in patients [1]. Its 
pathology includes sustained and severe 
pulmonary inflammation leading to an increase in 
permeability of pulmonary vessels, pulmonary 
edema and neutrophil infiltration inside the 
alveolar cavities, leading to impairment of 
respiratory functions [2].  
 
ALI is primarily caused due to Bacterial infection. 
The pathogenesis of ALI follows a multistep 
developmental process involving several 
inflammatory cells and mediators. Gram-negative 
bacteria have been recognized as the main 
cause of this infection. Lipopolysaccharide (LPS), 
present in the bacterial cell wall is an important 
virulence factor and is a primary factor known to 
cause the pulmonary inflammation [3,4]. LPS has 
been reported to cause ALI through several 
inflammatory mechanisms [5,6]. 
 
The transmembrane protein, Toll-like receptor 4 
(TLR4) acts as a transduction molecule during 
the pathogenesis of ALI [7]. TLR4 activates a 
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signaling pathway that plays an important 
function in the innate immunity against 
pathogens [8]. TLR4 also acts as a primary 
sensor of LPS and activates a downstream 
signal cascade. LPS binds to TLR4 which 
induces a pro-inflammatory MyD-88 dependent 
pathway and causes the expression of cytokines 
which is induced by the NF-κB activation [9]. 
TLR4 mediated NF-κB activation also induces 
cytokine generation. These cytokines include 
TNF-α and IL-6. Such cytokines are known to 
further activate more NF-κB molecules in a 
feedback loop, thus amplifying the pro-
inflammatory signal and playing a fundamental 
role in LPS-induced ALI [1]. 
 
Flavonoids are a group of natural substances 
known for their several anti-inflammatory and 
anti-oxidative properties [10]. Some flavonoids 
have previously been indicated for their role in 
ALI for example, Quercetin [11]. The natural 
flavonoid, Myricetin is abundantly found in plants, 
for example, berries, tea leaves and several 
medicinal plants [12]. Myricetin is known to 
possess anti-inflammatory properties [13]. 
Although anti-inflammatory properties of 
myricetin have been shown in previous studies, 
no study has yet shown its function in acute lung 
injury that was induced by LPS. In the present 
study, we explored, whether myricetin can 
potentially protect against LPS-induced ALI. 
Additionally, we also elucidated its potential 




Study animals and experimental design  
 
Sprague–Dawley rats (adult male, n = 120, 
weighing 250 to 300 g) were provided by the 
animal house of Tongren Hospital (Shanghai, 
China). The animals were kept in a 12 by 12 hour 
light and dark cycle and controlled temperature 
(22 - 24 °C) and humidity (40 - 60 %). Moreover, 
the rats were fed ad libitum, with the standard rat 
diet and water. The animal study was carried out 
after receiving approval from the institutional 
ethical committee of Shanghai Jiao Tong 
University School of Medicine (approval no. 
EME6231-F), and followed the guidelines of 
Principles of Laboratory Animal Care [14]. 
 
Myricetin and Escherichia coli LPS were 
procured from Sigma (USA). The animals were 
assigned to six groups at random viz. 1) Control 
(phosphate buffered saline, negative control-
treated); 2) Myricetin (40 mg/kg) group; 3) LPS 
group (5 mg/kg, administered through 
intratracheal instillation); (4) LPS + Myricetin (10 
mg/kg) group; (5) LPS+ Myricetin (20 mg/kg) 
group; (6) LPS + Myricetin (40 mg/kg) group. 
Saline and Myricetin were intra-peritoneally (i.p.) 
administered 30 minutes after LPS challenge. 
The rats were euthanized at 7 hours post-LPS 
administration. The euthanasia was followed by 
the collection of lung samples for subsequent 
experimental analysis. 
 
Estimation of ‘wet-to-dry’ weight ratio 
 
After euthanasia, the extent of pulmonary edema 
in the experimental groups was assessed by 
measuring the ‘wet-to-dry’ weight of the lungs. 
For this, the left lung was removed and 
immediately rinsed in phosphate buffer saline 
(PBS) and then and weighed to determine the 
lung ‘wet’ weight. Same lung was subsequently 
desiccated for 72 hours at 80 °C temperature in 
an oven. The lung was again weighted to 
estimate its ‘dry’ weight. To quantify pulmonary 
edema, the ratio of two values was calculated. 
 
Determination of the broncho-alveolar lavage 
(BAL) protein concentration and cell counts 
 
Broncho-alveolar lavage (BAL) was done by 
lavaging with 5 ml of PBS and a gentle 
aspiration. Approximately 90 % of the BALF was 
recovered. Centrifugation of the BALF was 
carried out at 1000 g for 30 min at 4 °C 
temperature. The estimation of total protein in the 
supernatants was performed by the Bradford's 
method and using the Protein Assay Dye (Bio-
Rad, USA). Protein estimation was performed by 
generating a standard curve of bovine serum 
albumin protein (BSA). Moreover, estimation of 
total cells count in the BALF was carried out post 
re-suspension of the cell pellet in 50 μl PBS. 
 
Evaluation of pulmonary myeloperoxidase 
(MPO) activity 
 
ALI is characterized by increased neutrophil 
accumulation in lungs. This elevated neutrophil 
accumulation can be detected by the MPO 
activity. For this, equal weights of the lung 
tissues were homogenized and centrifuged at 
15000 g for 30 min at 4 °C temperature. The 
supernatant thus separated was then evaluated 
for MPO activity using the MPO ELISA kit (Hycult 
Biotech, Netherlands) as per the manufacturer's 
protocol and absorbance was measured at 450 
nm. The absorbance of the samples was 
measured at 450 nm wavelength. All the 
evaluations were performed in replicates and the 
units were depicted in per gram. 
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Measurement of the pulmonary oxidative 
stress 
 
Excised lungs were homogenized at 10 % (w/v) 
and subsequently centrifuged at 15000 g and 4 
°C temperature for 30 minutes and the 
supernatant thus obtained was used for oxidative 
stress evaluations using colorimetric methods 
(spectrophotometer MARCEL S350 PRO).  
 
The activity of superoxide dismutase (SOD), 
malondialdehyde (MDA) and glutathione 
peroxidase (GPx) was estimated using 
Bioxytech-MDA-586 (OxisResearch, USA) and 
Ransod and RanseL kits (Randox Laboratories, 
Crumlin, UK), respectively. The activity of 
catalase (CAT) was determined by the 
breakdown of hydrogen peroxide at 37 °C. 
 
Examination of pulmonary histopathology 
 
The upper lobes of the right lungs were excised 
from all the six experimental groups. The 
pulmonary tissues were fixed in 8 % 
paraformaldehyde for 24 hours, dehydrated in 
ethanol and sliced into 4 µm sections after 
embedding them in paraffin. Post sectioning, the 
tissues were deparaffinized and subsequently 
stained using the hemotoxylin-eosin (H&E) stain. 
Histopathological variations in lungs were 




The concentrations of cytokines (IL-6 and TNF-α) 
in the BALF were estimated using ELISA kit (MN, 
USA), following the manufacturer's protocol. 
 
Western blot analysis 
 
Protein extracts (15 μg), separated by SDS-
PAGE and transferred onto PVDF membranes. 
The membranes were washed with 0.2 % Tween 
20 and blocked with 2 % non-fat dry milk. Binding 
of primary antibodies onto the membranes was 
performed by incubating it with primary antibody 
solution in TBST and 2 % NFDM for 8 hours at 4 
°C temperature.  
 
The blots were probed with antibodies TLR4, NF-
κB p65, p-NF-κB p65 and MyD88 (Santa Cruz 
Biotec. Inc. USA). The antibodies for IκB-α and 
p-IκB-α antibodies were procured from the Cell 
Signaling Tech., Inc. (USA). Finally, blots were 
incubated with horse radish peroxidase (HRP) 
conjugated secondary antibodies. The blots were 
developed using ECL system. Western blot 





The quantitative results were depicted as means 
± SEM. All the quantitative results were 
statistically analyzed by one-way analysis of 
variance (ANOVA). The analysis for multiple 
tests correction was performed by Bonferroni's 
method. All the statistical calculations were 
performed in Statistica 8 software program. The 
maximum threshold for statistically significant 




Effect of myricetin on pulmonary hyperper-
meability and edema  
 
Exposure to LPS caused 2.16-fold increase in 
the wet-to-dry weight ratio of the lungs (p < 0.01, 
Figure 1A) when compared to the negative 
control-treated animals. Additionally, the BALF 
protein concentration also showed a significant 
increase of 5.4-fold (p < 0.01, Figure 1B) in 
comparison to the negative control-treated 
animals. These two parameters were significantly 
reduced by myricetin treatment (p < 0.01), 
whereas, no statistically significant difference 
was observed in the total concentration of BALF 
protein and the wet-to-dry weight ratio between 





Figure 1: Effect of myricetin on (A) lung wet/dry 
weight ratio (B) total protein concentration in BALF in 
the LPS-induced ALI rats. The error bars indicate ± 
SEM (n = 20); # compared with control group; * 
compared with LPS group; # or * denotes p ≤ 0.05; ## 
or ** denotes p ≤ 0.01 
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Effect of myricetin treatment on MPO activity 
in lung tissues 
 
In comparison to animals of the negative control-
treated group, the MPO activity was found to be 
significantly increased (5.46-fold) in LPS-induced 
animals (Figure 2). However, treatment with 
myricetin caused 1.82 to 3.90-fold decrease (p < 
0.01) in the activity of MPO in animals that were 




Figure 2: Effect of myricetin on the MPO activity. The 
error bars indicate ± SEM (n = 20); # compared with 
control group; * compared with LPS group; # or * 
denotes p ≤ 0.05; ## or ** denotes p ≤ 0.01 
 
Effect of myricetin on the inflammatory cells 
count in the BALF  
 
LPS-induction 10.5-fold increase (p < 0.01) in the 
total BALF cell count. The cell count of 
neutrophils and macrophages also followed a 
similar trend (Figure 3). Upon administration of 
myricetin, a significant and large decrease in the 
BALF cell count was observed. 
 
Effect of myricetin on LPS-induced oxidative 
stress in lungs 
 
The levels of MDA were increased significantly (p 
< 0.05) in animals induced with LPS in 
comparison to that of the negative control-treated 
group (Table 1). Myricetin treatment reduced the 
MDA levels by 29, 60.8 and 72.4 % for 10, 20, 
and 40 mg myricetin treatment groups, 
respectively. The activity of three antioxidant 
enzymes viz. SOD, CAT, and GPx was 
significantly reduced upon LPS treatment in 
relation to negative control-treated animals. 
However, their activity was significantly restored 
(p < 0.05) upon treatment of myricetin. In all the 
three antioxidant enzymes the highest activity 




Effect of myricetin on the histopathologic 
variations 
 
Histological examination of the lung tissue was 
performed 7 hours post myricetin treatment. As 
depicted in the Figure 4A, the lung tissues of the 
negative control-treated animal group had a 
normal appearance and were devoid of any 
histopathological changes. It was observed that 
exposure to LPS treatment exhibited extensive 
damage to the lung tissue. The large scale 
intrusion of the inflammatory cells insides the 
pulmonary interstitium along with migration into 




Figure 3: Effect of myricetin on the numbers of total 
cells (A), neutrophils (B) and macrophages (C) in 
BALF of LPS-induced ALI rats. The error bars indicate 
± SEM (n = 20); # compared with control group; * 
compared with LPS group; # or * denotes p ≤ 0.05; ## 
or ** denotes p ≤ 0.01 
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Table 1: Effect of myricetin on oxidative stress biomarkers in the lung; mean ± SEM (n = 20); # compared with 
control group; * compared with LPS group; # or * denotes p ≤ 0.05; ## or ** denotes p ≤ 0.01 
 



































Figure 4: Histological estimation for the effects of myricetin on LPS-induced ALI. (A) Control, (B) myricetin (40 
mg/kg) and (C) LPS, (D) LPS + myricetin (10 mg/kg), (E) LPS + myricetin (20 mg/kg), (F) LPS + myricetin (40 
mg/kg) 
 
Moreover, the LPS treatment also resulted into 
pulmonary edema, hemorrhagia in the stroma, 
alveolar collapse, and alveolar wall thickening. 
The histology of myricetin treated animal group 
had close similarities with that of negative 
control-treated group (Figure 4B). The LPS group 
that was treated with myricetin showed 
significant attenuation of the histopathological 
changes especially in the group of animals that 
were treated with 20 mg and 40 mg/kg of 
myricetin (Figure 4D, Figure 4E and Figure 4F). 
 
Effect of myricetin on the BALF cytokine 
(TNF-α and IL-6) concentration 
 
The anti-inflammatory action of myricetin was 
further assessed by evaluating the concentration 
of the pro-inflammatory cytokines i.e. TNF-α and 
IL-6 in the BALF. Cytokine assay was performed 
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by ELISA at 7 hours post-LPS administration. 
The BALF concentrations of IL-6 and TNF-α was 
significantly increased (Figure 5A and Figure 5B) 
in the LPS-induced group. However, myricetin 
treatment caused 27.5- and 29.6-fold (p < 0.01) 
increase in the concentration of IL-6 and TNF-α, 
respectively. Western blotting was used to detect 
the expression of TLR4 and MyD88. The levels 
of TLR4 and MyD88 proteins showed a 
significant up-regulation in the LPS-induced 
group (Figure 6). However, this increase was 




Figure 5: Effect of myricetin on TNF-α and IL-6 
concentrations in the BALF. TNF-α (A) and IL-6 and 
(B). The error bars indicate ± SEM (n = 20); # 
compared with control group; * compared with LPS 
group; # or * denotes p ≤ 0.05; ## or ** denotes p ≤ 
0.01 
 
Effect of myricetin on NF-κB activation in 
lung tissues 
 
IκB-α and NF-κB p65 phosphorylation was 
estimated using immunological (western blot) 
analysis. These phosphorylations reflected the 
NF-κB activation in pulmonary tissues. As 
illustrated in Figure 7, administration of LPS 
induction resulted in 17- and 11-fold increase (p 
< 0.01) in the NF-κB p65 and IκB-α 
phosphorylation in comparison to the negative 
control-treated group. However, a significantly 
large down-regulation in the phosphorylation of 
NF-κB p65 and IκB-α was observed when 




Figure 6: Effect of myricetin on the expression of 
TLR4 and MyD88 in pulmonary tissues. (A) Western 
blot analysis of TLR4 and MyD88. Data for TLR4 (B) 
and MyD88 (C) levels, compared with control. The 
error bars indicate ± SEM (n = 20); # compared with 
control group; * compared with LPS group; # or * 




The anti-inflammatory and anti-oxidative effects 
of myricetin on the LPS-induced ALI in rats were 
identified. This study also attempts to determine 
the potential mechanism of action of myricetin on 
pulmonary inflammation. This is the first such 
study on myricetin, a natural flavonoid found in 
several plants.  
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Figure 7: Effect of myricetin on phosphorylation of NF-
κB p65 and IκB-α in lung tissues. (A) Western blot of 
p-NF-κB p65, NF-κB p65, p-IκB-α and IκB-α where β-
actin was used as control, the phosphorylation of NF-
κB p65 and (B) IκB-α (C) were detected by western 
blot densitometry. The error bars indicate ± SEM (n = 
20); # compared with control group; * compared with 
LPS group; # or * denotes p ≤ 0.05; ## or ** denotes p 
≤ 0.01 
 
Results showed a significant attenuation of lung 
inflammation which was evident from parameters 
such as decreased wet-to-dry weight ratio of the 
lungs, the concentration of BALF protein, the 
activity of MPO, cytokine production and 
migration of inflammatory cells. Moreover, the 
expression of TLR4, NF-κB and MyD88 were 
also found to be significantly decreased. 
Moreover, in all the treatment groups a 
significantly large increase in the antioxidant 
enzyme (SOD, GPx and CAT) activity was 
observed. 
 
Pulmonary inflammation and edema are typical 
signs of ALI [15]. Increase in the wet-to-dry 
weight ratio of the lungs and an elevated BALF 
protein concentration due to protein 
extravasation are strong indicators of pulmonary 
inflammation and edema [16]. Both of these 
parameters were significantly increased upon 
LPS-induction and there was a subsequent 
significant decrease after myricetin treatment. 
These results indicated attenuation of lung 
edema and leakage of vesicles in LPS-
challenged rats after myricetin treatment.  
 
Pulmonary edema indicated by the wet-to-dry 
ratio of lungs as well as the BALF protein 
concentration was further confirmed by the 
observations in lung histology. We observed 
several inflammatory changes in our rat ALI-
model for example, pulmonary edema, thickening 
of pulmonary epithelium and migration of the 
inflammatory cells into the pulmonary interstitial 
spaces. A marked improvement in the 
histopathology of lungs was noticed when the 
LPS-induced rats were treated with myricetin. 
This observation provided a direct proof of the 
effectiveness of myricetin in the LPS-induced 
ALI, apart from the various measured 
parameters.  
 
Infiltration of neutrophils into pulmonary cavities 
is one of the hallmarks of ALI [15]. After LPS-
induction, neutrophils migrate across the 
pulmonary endothelium and epithelium and 
reach the alveolar spaces. Here, the activated 
neutrophils cause elevated production of ROS, 
the release of MPO, cytotoxic and pro-
inflammatory mediators and increase in 
microvascular permeability [17]. Therefore, the 
persistent presence of neutrophils in the 
pulmonary cavity is a strong indicator of ALI. In 
this study, upon myricetin treatment, the total cell 
count in BALF and also neutrophil and 
macrophage count were significantly decreased. 
Neutrophils and alveolar macrophages are 
known to release MPO during acute inflammation 
of the lungs [18]. Increased activity of MPO is a 
strong indicator of neutrophil migration into the 
pulmonary parenchyma and the alveolar cavities 
[19]. MPO concentration has been used for 
estimation of LPS-induced ALI in many studies 
for example, D Rittirsch et al and CL Tsai et al 
[20,21]. In the myricetin treated rats, as 
compared to LPS treated mice, a marked 
reduction in the activity of MPO was found. This 
further indicated a reduced neutrophil infiltration 
and diminished inflammation of lungs. 
 
ROS are produced by activated cytokines [22]. 
ROS can cause several damages to lung tissue 
such as DNA damage, protein oxidation, and 
lipid peroxidation. Heightened levels of MDS and 
reduced levels of pulmonary anti-oxidants (GPx, 
SOD, CAT) in the LPS-induced ALI were 
observed. These levels were significantly 
normalized upon myricetin treatment. In addition 
to being an anti-inflammatory agent, myricetin 
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was also known to possess antioxidant 
properties [23]. 
 
The release of cytokines is known to have an 
important function in the pathogenesis of ALI, for 
instance, the hyper permeability of the capillary-
alveolar barrier [24]. The cytokines like IL-6 and 
TNF-α have also been reported to be involved in 
the development of LPS-induced acute lung 
injury [25]. In our results, the BALF levels of IL-6 
and TNF-α showed marked increase upon 
induction with LPS. However, after administration 
of myricetin these levels decreased significantly 
and came down to almost normal levels 
(compared to negative control-treated).  
 
Several studies in past have shown the 
regulatory function of NF-κB in the inflammatory 
and immunological responses in ALI [26]. TLR4-
MyD88-NF-κB signaling pathway is widely 
reported to have an important function in the 
inflammatory signaling of ALI [9]. The 
concentration of these mediators was determined 
by western blot densitometry which indicated the 
role of this pathway in case of anti-inflammatory 
action by myricetin. In our results, the TLR4-
MyD88-NF-κB pathway was found to be 
significantly upregulated in LPS-induced animals. 
This was also corroborated by the increased 
phosphorylation of NF-κB and IκB-α, observed in 
the western-blot. After treating LPS-induced ALI 
rats with myricetin, an effective inhibition of the 




The decreased expression of cytokines and 
TLR4-MyD88-NF-κB pathway upon treatment 
with the plant flavonoid, myricetin, clearly 
indicated its anti-inflammatory effect on NF-κB 
signaling. Thus, myrecitin is a promising 
therapeutic agent for the treatment of ALI. 
However, further studies are required to 
elucidate the molecular mechanism responsible 
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